Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis
Authors' conclusion
In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.
Study context
- Population
- Adults with overweight/obesity (and T2D in STEP 2 only), STEP 1–3 and 5; excluded severe major depressive disorder within 2 years or PHQ-9 score ≥15; subgroups by baseline antidepressant use (on/off)539 on antidepressants
- Participants
- 3,683 adults
- Comparison
- Semaglutide 2.4 mg vs placebo, by baseline antidepressant use
- Primary endpoint
- Mean body weight change from baseline
- Follow-up
- Week 68
Methodological detailsexploratory, placebo-controlled
- Exploratory
- Placebo-controlled
Primary result
As reported in the abstract
Body weight change from baseline, STEP 1
STEP 1, on antidepressants: semaglutide vs placebo
−15.7% vs −0.2%
STEP 1, not on antidepressants: semaglutide vs placebo
−14.7% vs −2.8%
Safety
Adverse events, participants on antidepressants
- Prevalence of adverse events (AEs) generally similar between semaglutide and placebo in participants on antidepressants at baseline
Original publication
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis. Obesity (Silver Spring). Published 21 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →